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Objective: To investigate the inﬂuence of lactulose on immunity of hepatocellular car-
cinoma (HCC) patients with hepatocirrhosis and hypersplenism after double-
interventional therapies.
Methods: A total of 40 HCC patients with hepatocirrhosis and hypersplenism, hospi-
talized during January 2013 to June 2014, were enrolled and randomized into control
group and observation group. Both groups received partial splenic embolization com-
bined with transcatheter arterial chemoembolization. Besides, observation group orally
took lactulose 30 mL/d. Four days before interventional therapies and at days 1, 3, 7 and
14 after therapies, fasting venous blood was collected to detect white blood cell count, red
blood cell count (RBC), and platelet count (PLT). Four days before therapies and at days
7 and 14 after therapies, the levels of alanine aminotransferase, aspartate transaminase,
total bilirubin, malondialdehyde, super-oxide dismutase (SOD), IFN-g, and IL-4 as well
as the distribution of T cell subsets in peripheral blood were tested. Complications were
observed after interventional therapies.
Results: Before interventional therapies the levels of white blood cell count, PLT and
RBC in both groups showed no difference, while after interventional therapies the levels
of PLT and RBC in both groups showed an increasing tendency (P < 0.05). At day 14
after interventional therapies, the level of blood cell as well as that of SOD, IFN-g and IL-
4 in serum were signiﬁcantly higher than that before therapies; meanwhile, the levels of
alanine aminotransferase and total bilirubin of observation group after therapies were
signiﬁcantly lower than before and control group (P < 0.05), the levels of CD4+/CD8+,
SOD and IFN-g were all higher than before and control group (P < 0.05).
Conclusions: Oral administration of lactulose could adjust the imbalance of oxidation
system/antioxidant system in HCC patients with hepatocirrhosis and hypersplenism after
interventional therapies, and improve the antitumor immunity and prognosis.1. Introduction
Hepatocellular carcinoma (HCC) is one of the most common
types of malignant liver cancer with high morbidity andmortality.
In the past decades, the global morbidity of HCC has been on a
sharp upward trend; themorbidity of HCC inUnited States is eventwice as much as the average level of the world [1]. As most
patients are already at the advanced stage when HCC is
diagnosed, the tumors are often inoperable. Therefore, palliative
therapy is the principle therapeutic method of HCC. Among all
the palliative therapies, transcatheter arterial chemoembolization
(TACE) is most frequently adopted. It can signiﬁcantly increase
survival of HCC patients with unresectable tumors [2–4]. It's
reported that about 80% of HCC patients have hepatocirrhosis,
because HCC mostly develops from hepatocirrhosis or liver
ﬁbrosis. In addition, hepatocirrhosis usually also causes portal
hypertension and hypersplenism. Recent studies have shown
that partial splenic embolization (PSE) can permanently
improve thrombocytopenia and hypersplenism caused by portal
hypertension [5].der the CC BY-NC-ND license (http://
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balance and excretion; therefore, it is widely used in the treat-
ment of hepatic encephalopathy and constipation [6,7]. The
pharmacokinetic characteristics of lactulose make it an
effective and safe option for the treatment of such indications.
However, many of its potential effects are still unknown. In
this study, HCC patients with hepatocirrhosis and
hypersplenism received lactulose orally, to investigate the
inﬂuence of lactulose on the efﬁcacy of interventional therapy
and antioxidant system, thus providing theoretical basis for the
comprehensive treatment of the disease.
2. Materials and methods
2.1. General data
A total of 40 HCC patients with hepatocirrhosis and hyper-
splenism, hospitalized during January 2013 to June 2014, were
chosen as subjects. The diagnosis of HCC ﬁts in with relevant
guidelines [8], and the diagnosis of hypersplenism should ﬁt in
with the following criteria: type-B ultrasound or CT scan
shows hepatocirrhosis, spleen pachydiameter >4.1 cm, class I
splenomegaly, white blood cell count (WBC) <3 × 109/L, and
platelet count (PLT) <100 × 109/L [9]. The liver condition of all
patients was either Child–Pugh A or Child–Pugh B. No patient
had taken immunomodulator within 30 d before the treatment.
The patients were randomly divided into control group and
observation group, with 20 patients in each group. Double
intervention with TACE and PSE began after no patient was
found contraindications.
2.2. Therapeutic methods
In case there might be ascites, sufﬁcient support therapy was
given to all patients before the intervention. During the proce-
dure, all patients ﬁtting in with the inclusion criteria received
PSE ﬁrst, and then TACE. PSE procedures: The catheter was
inserted into the femoral artery via Seldinger method, following
with abdominal angiogram and selective splenic arteriography to
observe the distribution of splenic artery and routes of collateral
circulation. Then, the tip of the catheter was placed at the splenic
hilum and the gelatin sponge was suspended in the contrast
media to form embolization; the scope of splenic embolization
was assessed by angiogram. When a 40%–60% ablation of the
splenic parenchyma was obtained, the embolization was termi-
nated. After the PSE procedure, TACE was performed under
aseptic condition: the catheter was inserted into the femoral ar-
tery as in the PSE procedure, following with abdominal angio-
gram and selective splenic arteriography to observe tumor
blood-supply, the distribution of hepatic artery and routes of
collateral circulation. The tip of the catheter was placed at the
feeding artery of the tumor and embolization was performed
using an emulsion mixture of lipoidal ultra-ﬂuid, perarubicin and
DDP (the dose of embolization depends on tumor size, blood-
supply and hepatic function of the patient). When the tumor was
ﬁlled well with emulsiﬁer, the embolization was terminated.
In addition, from day 3 before the interventional therapies to
day 14 after therapies, the observation group took lactulose
orally; the control group took placebo. For the observation
group, lactulose syrup was administered as 30 mL/d in divided
doses for a stool frequency of two to three soft defecations per
day.2.3. Observation items
Clinical symptoms and complications were observed after the
interventional therapies. Four days before interventional thera-
pies and at days 1, 3, 7 and 14 after them, fasting venous blood
was collected to detect WBC, red blood cell count (RBC), and
PLT. Four days before interventional therapies and at days 7 and
14 after them, levels of alanine aminotransferase (ALT), aspar-
tate transaminase (AST) and total bilirubin (TBil) were tested;
meanwhile, peripheral venous blood was collected for
measuring levels of CD4+ T cell and CD8+ T cells by ﬂow
cytometry, in order to obtain the ratio of CD4+/CD8+.
Four days before interventional therapies and at days 7 and
14 after them, fasting blood sample was collected; thiobarbituric
acid chromatometry was used to assay the content of malon-
dialdehyde (MDA) in blood, xanthin oxidase method was used
to assay the content of super-oxide dismutase (SOD), and
ELISA was used to detect the levels of IFN-g and IL-4 in serum.
All reagent kits were bought from Shijiazhuang Huarui Biotech
R&D Center.
2.4. Data statistics
SPSS l6.0 software was used for statistical analysis and all
the data was represented by mean ± SD. The paired t-test was
used to compare the indexes of the same group before and after
the procedure; the independent t-test was used to compare the
indexes of two groups; enumeration data was compared by c2
test. When P < 0.05, the differences were considered statistically
signiﬁcant.
3. Results
3.1. Levels of peripheral blood cell and transaminase
after interventional therapies
After interventional therapies, WBC content and PLT content
of both groups showed signiﬁcant increase compared with the
preoperative content (P < 0.05); at day 14 after interventional
therapies, levels of ALT and TBil of the observation group
patients were higher than preoperative levels and those of con-
trol group (P < 0.05); concerning the RBC and AST level, the
post-treatment level in both groups showed no signiﬁcant dif-
ference compared with the preoperative level (Table 1).
After the therapies, both groups showed a slowly rising trend
on the percentage of CD4+ T cell, but a slowly decreasing trend
on the percentage of CD8+ T cell; at day 14 after the therapies,
the ratio of CD4+/CD8+ in the observation group was signiﬁ-
cantly higher than that before therapies (P < 0.05).
3.2. Levels of SOD, MDA, IFN-g and IL-4 before and
after interventional therapies
According to Table 2, at day 14 after interventional therapies,
levels of SOD, IFN-g and IL-4 in both groups increased
signiﬁcantly, while the observation group showed higher levels
of SOD and IFN-g than the control group (P < 0.05). At day 14
after therapies, MDA content of the observation group was
signiﬁcantly lower than that before therapies (P < 0.05); how-
ever, there was no signiﬁcant change in MDA content of the
control group (P > 0.05).
Table 1
Blood cells and aminotransferase contents at different time points.
Groups WBC level (×109/L) PLT level (×109/L) RBC level (×1012/L) ALT (U/L) AST (U/L) TBil (mmol/L)
Control group Pre Op 2.57 ± 0.61 52.81 ± 7.44 3.22 ± 0.51 54.43 ± 17.62 52.06 ± 17.08 26.61 ± 9.55
POD 1 4.32 ± 1.47* 63.04 ± 9.20 3.26 ± 0.48 – – –
POD 3 7.72 ± 1.32* 76.54 ± 10.85* 3.31 ± 0.67 – – –
POD 7 6.85 ± 0.92* 117.07 ± 14.35* 3.42 ± 0.71 54.75 ± 14.63 51.52 ± 15.93 26.48 ± 10.11
POD 14 6.04 ± 0.82* 148.73 ± 17.50* 3.39 ± 0.55 55.02 ± 17.21 51.22 ± 15.04 25.74 ± 8.96
Observation group Pre Op 2.59 ± 0.52 54.02 ± 9.21 3.19 ± 0.47 54.78 ± 15.40 51.43 ± 16.45 25.94 ± 8.54
POD 1 4.97 ± 0.80* 71.25 ± 11.62 3.37 ± 0.62 – – –
POD 3 8.54 ± 1.26* 89.20 ± 7.26* 3.62 ± 0.42 – – –
POD 7 7.69 ± 1.03* 137.51 ± 6.57* 3.88 ± 0.56 50.11 ± 16.55 45.30 ± 13.82 22.14 ± 7.23
POD 14 6.95 ± 1.22* 155.94 ± 18.93* 3.71 ± 0.61 41.33 ± 15.74*,# 40.66 ± 10.95 18.22 ± 6.90*,#
Note: Pre Op: pre-operation; POD: postoperative day. * vs. Pre Op, P < 0.05; # vs. control group, P < 0.05.
Table 2
Levels of serum antioxidants and cytokines at different time points before and after interventional therapies.
Groups SOD (U/mL) MDA (nmol/mL) IFN-g (pg/mL) IL-4 (pg/mL)
Control group (n = 20) Pre Op 168.57 ± 14.98 6.72 ± 2.01 4.37 ± 0.94 5.92 ± 1.94
POD 7 207.35 ± 18.71* 5.89 ± 1.74 5.22 ± 1.20* 6.81 ± 2.15
POD 14 218.40 ± 20.34* 5.78 ± 1.65 5.65 ± 1.54* 7.32 ± 2.21*
Observation group (n = 20) Pre Op 169.34 ± 16.30 6.68 ± 1.69 4.32 ± 0.97 5.87 ± 1.82
POD 7 219.64 ± 16.94* 5.75 ± 1.33 5.67 ± 1.31* 6.99 ± 2.30
POD 14 269.04 ± 22.17*,# 5.47 ± 1.82* 6.78 ± 1.72*,# 7.67 ± 2.46*
Pre Op: pre-operation; POD: postoperative day. * vs. Pre-operation, P < 0.05; # vs. control group, P < 0.05.
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therapies
After interventional therapies, patients of both groups suf-
fered pain, fever, nausea and vomiting, and left sub-
diaphragmatic effusion. However, in generally, two groups
showed no difference in complications incidence (P > 0.05).
4. Discussion
In clinic, lactulose is mainly used in the treatment of con-
stipation and hepatic encephalopathy. In fact, its effects are far
more than that. It can also reduce endotoxin, affect trace element
metabolism, regulate intestinal ﬂora balance, affect the circula-
tion of bile acid, resist oxidation, and strengthen immunity and
so on. In the study, all patients received double-interventional
therapies. Moreover, lactulose was given to patients of obser-
vation group to observe the inﬂuence of lactulose on therapeutic
effect. Our results showed that the observation group and the
control group showed no difference in the levels of blood cell
and transaminase after the therapies and also in the postoperative
complications incidence. However, levels of antioxidant enzyme
and cytokines were more signiﬁcantly improved in patients
having taken lactulose than in those having not (P < 0.05).
Hepatocirrhosis is the advanced stage of chronic liver dis-
ease, which is a result of various repeated or long-term damages
to the liver. In China, hepatocirrhosis is mainly caused by viral
hepatitis and develops from liver ﬁbrosis [10]. Although
hepatocirrhosis is the result of many factors, the role of
oxidative stress should not be ignored, which inﬂuences the
development of hepatocirrhosis from various aspects [11,12]. It
has been veriﬁed that the reactive oxygen species (ROS) can
induce lipid peroxidation leading to inﬂammation and
ﬁbrogenesis through the activation of stellate cells [13]. In
addition, ROS is the critical mediator of liver ﬁbrosis, and italso contributes to hepatic ﬁbrosis from various kinds of liver
injuries [12,14]. SOD is an antioxidant enzyme that constitutes
the ﬁrst line of defense against ROS. It reﬂects the body's
ability and degree of reducing free radical. MDA represents
the change of ROS content and the degree of lipid
peroxidation and indirectly reﬂects the degree of ROS's
damage to tissues. Joint detection of MDA and SOD can
indicate the body's condition of oxidation and peroxidation.
This study found that lactulose can signiﬁcantly improve
patients' postoperative level of SOD and meanwhile inhibit
MDA content, which indicated that lactulose can improve the
curative effect of interventional therapy by reducing oxidative
stress. Yu et al. [15] investigated the potential inﬂuence of
lactulose administration on liver regeneration, and they
concluded that lactulose administration accelerates
posthepatectomized liver regeneration in rats by inducing
hydrogen, which may result from attenuation of the oxidative
stress response and excessive inﬂammatory response. In the
mouse model of human ulcerative colitis, Chen et al. [16]
found that lactulose can prevent the development of DSS-
induced colitis and alleviate oxidative stress in the colon,
probably by increasing endogenous H2 production. In a word,
lactulose can eliminate free radicals, adjust the imbalance be-
tween oxidation system and antioxidant system, and alleviate
liver injury.
Cellular immunity often plays an important role in tumor
immunity. When the body has strong antitumor immunity, there
is mainly the secretion of Th1 cytokines; while there is mainly
the secretion of Th2 cytokines, the body's antitumor immunity is
inhibited. IFN-g and IL-4 are representative cytokines respec-
tively produced by Th1 cells and Th2 cells. The study showed
that at day 14 after interventional therapies, the level of IFN-g in
observation group was signiﬁcantly higher than that in control
group, while the two groups showed no difference in the level of
IL-4, which suggested that Th1/Th2 cell polarization evidently
Deng-Wei Zong et al./Asian Paciﬁc Journal of Tropical Medicine 2016; 9(2): 193–196196shifted to Th1 cells, and patients' antitumor immunity was
signiﬁcantly enhanced after the administration of lactulose.
Vendemiale et al. [17] also found the effect of activation on cell-
mediated immune system depressed during liver cirrhosis, pro-
duced by lactulose. There are many other studies having
conﬁrmed the positive role of lactulose on the immune defense
and immune regulation [18,19]. However, further studies are still
needed to conﬁrm and clarify the possible mechanisms involved.
In summary, oral administration of lactulose could adjust the
imbalance between the oxidation system and the antioxidant
system of HCC patients with hepatocirrhosis and hypersplenism
after interventional therapies, alleviate liver injury, improve the
antitumor immunity and prognosis.
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